Literature DB >> 18842457

WISECARE+: Results of a European study of a nursing intervention for the management of chemotherapy-related symptoms.

Nora Kearney1, Morven Miller, Roma Maguire, Shelley Dolan, Roseanne MacDonald, Joan McLeod, Louise Maher, Lesley Sinclair, John Norrie, Yvonne Wengström.   

Abstract

While the use of chemotherapy has significantly improved survival rates, the symptoms associated with chemotherapy remain a major burden for patients. Preventing or appropriately managing side effects significantly improves patients' functional status and quality of life, ultimately leading to greater patient acceptance of chemotherapy. However, symptom assessment and management are fraught with difficulties such as poor patient recall, retrospective assessment conducted by clinicians and lack of appropriate, clinically relevant and patient friendly symptom assessment and management tools. Furthermore the differences between clinician and patient perceptions of stresses and distress during chemotherapy are well recognised. This study aimed to evaluate the impact of a nursing intervention incorporating structured symptom assessment and management, facilitated by information technology, on chemotherapy-related symptoms, nausea, vomiting, fatigue and mucositis. This pan-European study, involved 8 clinical sites from Belgium, Denmark, England, Ireland and Scotland. Adults (n=249) receiving first line chemotherapy for breast, lung, ovarian or colorectal cancer, osteosarcoma, acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL) or lymphoma were recruited to the study. Patients completed daily symptom assessment questionnaires for 14 days following consecutive cycles of chemotherapy. Symptom outcomes were compared before and after the introduction of the intervention with positive impact on patients' experiences of nausea, vomiting and oral problems. Fatigue was not significantly improved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842457     DOI: 10.1016/j.ejon.2008.07.005

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  9 in total

Review 1.  Health-related quality of life in ovarian cancer patients and its impact on clinical management.

Authors:  Dana M Chase; Lari Wenzel
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

2.  Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.

Authors:  Marcin Mardas; Marta Stelmach-Mardas; Radosław Madry
Journal:  Support Care Cancer       Date:  2016-10-22       Impact factor: 3.603

3.  Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer.

Authors:  Gunilla Pettersson; Carina Berterö; Mitra Unosson; Sussanne Börjeson
Journal:  Support Care Cancer       Date:  2013-12-13       Impact factor: 3.603

4.  Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.

Authors:  Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Gibbons; Bradley J Monk; Peter G Rose; Deborah K Armstrong; David Cella; Lari Wenzel
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

Review 5.  Benefits of remote real-time side-effect monitoring systems for patients receiving cancer treatment.

Authors:  Sarah Kofoed; Sibilah Breen; Karla Gough; Sanchia Aranda
Journal:  Oncol Rev       Date:  2012-06-05

6.  The Patient Remote Intervention and Symptom Management System (PRISMS) - a Telehealth- mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised controlled trial.

Authors:  Sibilah Breen; David Ritchie; Penelope Schofield; Ya-Seng Hsueh; Karla Gough; Nick Santamaria; Rose Kamateros; Roma Maguire; Nora Kearney; Sanchia Aranda
Journal:  Trials       Date:  2015-10-19       Impact factor: 2.279

7.  Link between diet and chemotherapy related gastrointestinal side effects.

Authors:  Marcin Mardas; Radosław Madry; Marta Stelmach-Mardas
Journal:  Contemp Oncol (Pozn)       Date:  2017-06-30

8.  Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer.

Authors:  Monika K Krzyzanowska; Cassandra MacKay; Heekyung Han; Maria Eberg; Sonal Gandhi; Nicole B Laferriere; Melanie Powis; Doris Howell; Clare L Atzema; Kelvin K W Chan; Vishal Kukreti; Sandra Mitchell; Marla Nayer; Mark Pasetka; Dafna Knittel-Keren; Erin Redwood
Journal:  Pilot Feasibility Stud       Date:  2019-03-08

9.  Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.

Authors:  Monika K Krzyzanowska; Jim A Julian; Melanie Powis; Doris Howell; Craig C Earle; Katherine A Enright; Nicole Mittmann; Maureen E Trudeau; Eva Grunfeld
Journal:  BMC Cancer       Date:  2019-09-05       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.